Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANFIRE trial of canakinumab for anemia in lower-risk MDS or MDS/MPN
2024-515886-33-00Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Leipzig University. Primary endpoint: Documented achievement of erythroid response (HI-E). Started Mar 2022; status: completed.
02
Drugs
canakinumab
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on 2024-515886-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515886-33-00.